Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell Limited announced the successful outcomes of its Annual General Meeting, where all resolutions, including a special resolution to amend the Constitution, were passed. This development signifies strong shareholder support and may enhance the company’s governance framework, potentially impacting its strategic direction and stakeholder relations positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Its portfolio includes collagen medical devices for dental and orthopedic applications, with products like Striate+™ and Remplir™ cleared for use in multiple countries. The company is also advancing tendon cell therapy in the US.
Average Trading Volume: 758,584
Technical Sentiment Signal: Buy
Current Market Cap: A$314.2M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.